SCIENTIFIC POSTER 2016_Results of Intravitreal Aflibercept in Insufficient Responders to Prior Anti-VEGF Therapy in Neovascular AMD Zeynep Alkin


To report the outcomes of intravitreal aflibercept therapy in eyes with refractory neovascular age-related macular degeneration (AMD) switched from intravitreal bevacizumab or ranibizumab.


This is a retrospective review of eyes with neovascular AMD switched to intravitreal aflibercept. All patients had a minimum of 3 injections of bevacizumab or ranibizumab before the switch. Changes in best-corrected visual acuity, fluid on optical coherence tomography, central retinal thickness and the number of injections were evaluated.


Seventy-one eyes of 63 patients were analyzed. The mean age was 72.1 years.The mean follow-up time was 32 months, the mean number of injections 11.6 and the mean visual acuity (LogMar) was 0.67 prior to the switch. With the switch, central macular thickness showed a decrease from 384 µm to 321 µm (p=0.29).


Aflibercept appears to be a valuable treatment choice for the management of patients with poor response to ranibizumab and bevacizumab. Patients could have anatomic improvement with intravitreal aflibercept.

Contact Details:

Cell Phone: +905052703658